AbbVie is highlighted as an underrated dividend growth stock, maintaining a strong track record of dividend increases since its spinoff from Abbott Laboratories, with a current forward yield of around 3% and expected earnings growth. Despite facing competition and market challenges, AbbVie is positioned for continued dividend growth due to robust product performance and sustainable payout ratios.
For an investor focused on dividend growth and value, AbbVie stands out as a strong candidate. Despite its established status and strong dividend track record, it is not currently overvalued compared to many popular consumer staples stocks. With a forward dividend yield of around 3% and ongoing earnings growth, AbbVie offers a compelling mix of value, growth, and yield, making it a notable option for a diversified dividend-focused portfolio.